First-line palliative HER2-targeted therapy in HER2-positive metastatic breast cancer is less effective after previous adjuvant trastuzumab-based therapy

Hánah N. Rier*, Mark David Levin, Joost Van Rosmalen, Monique M.E.M. Bos, Jan C. Drooger, Paul De Jong, Johanneke E.A. Portielje, Elisabeth M.P. Elsten, Albert Jan Ten Tije, Stefan Sleijfer, Agnes Jager

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

16 Citations (Scopus)
2 Downloads (Pure)

Fingerprint

Dive into the research topics of 'First-line palliative HER2-targeted therapy in HER2-positive metastatic breast cancer is less effective after previous adjuvant trastuzumab-based therapy'. Together they form a unique fingerprint.

Nursing and Health Professions

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology